VUNO Achieves Major Profitability Milestone in Q3 2025 as DeepCARS Thrives

VUNO Inc., a prominent player in the medical AI landscape, recently made headlines with its remarkable financial results for the third quarter of 2025. The company announced a substantial profit, showcasing its impressive growth over the past three months, driven primarily by its flagship product, VUNO Med®–DeepCARS®.

In a report released on November 12, 2025, VUNO revealed consolidated revenues of KRW 10.8 billion for Q3, marking a significant increase of approximately 58% from the KRW 6.9 billion reported during the same period last year. This growth not only reflects VUNO's ongoing operational efficiency but also its expanding footprint in the medical AI market. Notably, this quarter represents a pivotal moment as it marks the company's first-ever quarterly revenue exceeding KRW 10 billion since its inception in 2014.

The overall revenue growth is attributed to improved management efficiency and the performance of VUNO's core products, with DeepCARS alone contributing KRW 7.0 billion to the total. This represents an 18% year-on-year increase for the product, underlining its vital role in the company’s expansion and profitability outlook. Joon Kim, VUNO’s Chief Financial Officer, expressed optimism regarding the company’s financial foundation, attributing stable revenue to the growing demand for their medical AI solutions.

The cumulative revenue for the first three quarters of 2025 has reached KRW 27.6 billion, surpassing the entire revenue for the previous year, which stood at KRW 25.9 billion. This achievement ahead of the timeline reflects VUNO’s progressive execution of its growth strategies and customer acquisition efforts in delivering cutting-edge healthcare solutions. According to VUNO, the company aims to establish a sustainable profit model while aggressively pursuing international market opportunities.

VUNO Med®-DeepCARS® is recognized as a leading AI solution in South Korea's medical field, providing predictions regarding the risk of in-hospital cardiac arrest within a 24-hour window for patients located in general wards. As it stands, DeepCARS is currently operating in around 50,000 hospital beds across the nation, with collaborations and potential expansions on the horizon.

Plans are underway for VUNO to launch pilot tests in Europe, bolstered by its recent CE-MDR certification. Concurrently, the company is pursuing FDA clearance for its solution in the United States. By actively promoting its capabilities at critical care conferences, VUNO is establishing strategic partnerships with notable U.S. hospital systems, positioning itself for expedited integration into the U.S. healthcare market.

Founded in 2014, VUNO is proud to stand as a leading South Korean medical AI firm, significantly contributing to the advancement of healthcare technologies. Its efforts focus on leveraging sophisticated AI to analyze medical data, including bio-signals such as ECG, as well as medical imaging like X-rays and CT scans. The goal is to enhance clinical decision-making and ultimately improve patient outcomes.

The commitment to innovation and patient-centered care remains at the heart of VUNO’s mission as it strives to make high-quality healthcare accessible to individuals worldwide, emphasizing a future where AI-assisted medical technologies redefine the healthcare landscape for the better.